A private venture-backed US biotech company was developing a biologic through late-stage drug discovery and wished to quantify the commercial opportunity for the product in treating anemia in irritable bowel disease (IBD). Alacrita was commissioned to perform a critical analysis of the current treatment landscape in IBD and to provide opinions on whether anemia in IBD was a strong therapeutic area to target.


Alacrita performed an initial secondary research analysis to gain an insight into the size of the potential opportunity and the degree of product impact required. This was used to build a forecasting model for the addressable patient population and potential revenue for the product. We next conducted primary research among IBD and hematology clinicians to confirm our assumptions and further understand the unmet need. Our research and conclusions were condensed into a full analysis report and delivered to the client to support presentation of the opportunity to its board. 

Explore our strategy and commercialization consulting support

Whether you need guidance charting your optimal path to market, technical or market insight to prioritize your R&D portfolio, or strategic support to help you best position your biotech or program for a fundraising round, we can assist. Our consultants average 20-30 years of industry experience and bring significant first-hand knowledge to every project.

Related Case Studies